WO2005094850A1 - 抗菌性組成物 - Google Patents
抗菌性組成物 Download PDFInfo
- Publication number
- WO2005094850A1 WO2005094850A1 PCT/JP2005/006253 JP2005006253W WO2005094850A1 WO 2005094850 A1 WO2005094850 A1 WO 2005094850A1 JP 2005006253 W JP2005006253 W JP 2005006253W WO 2005094850 A1 WO2005094850 A1 WO 2005094850A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- antibacterial
- liquid food
- culture
- fermented milk
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 100
- 239000000203 mixture Substances 0.000 title claims description 89
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 235000015140 cultured milk Nutrition 0.000 claims abstract description 30
- 235000014048 cultured milk product Nutrition 0.000 claims abstract description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 74
- 239000004310 lactic acid Substances 0.000 claims description 37
- 235000014655 lactic acid Nutrition 0.000 claims description 37
- 235000021001 fermented dairy product Nutrition 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 19
- 150000001720 carbohydrates Chemical class 0.000 claims description 16
- 235000014633 carbohydrates Nutrition 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 235000013351 cheese Nutrition 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 8
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 abstract description 62
- 230000007935 neutral effect Effects 0.000 abstract description 21
- 206010041925 Staphylococcal infections Diseases 0.000 abstract description 20
- 235000013305 food Nutrition 0.000 abstract description 20
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 abstract description 20
- 241000192125 Firmicutes Species 0.000 abstract description 15
- 239000007858 starting material Substances 0.000 abstract description 7
- 235000013618 yogurt Nutrition 0.000 abstract description 5
- 239000012530 fluid Substances 0.000 abstract 5
- 238000011109 contamination Methods 0.000 abstract 1
- 230000005180 public health Effects 0.000 abstract 1
- 235000021056 liquid food Nutrition 0.000 description 83
- 241000894006 Bacteria Species 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 23
- 241000191967 Staphylococcus aureus Species 0.000 description 12
- 150000007524 organic acids Chemical class 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 235000013325 dietary fiber Nutrition 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 235000013336 milk Nutrition 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- 108010046377 Whey Proteins Proteins 0.000 description 9
- 102000007544 Whey Proteins Human genes 0.000 description 9
- 235000011054 acetic acid Nutrition 0.000 description 9
- 208000002925 dental caries Diseases 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000005862 Whey Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 235000020183 skimmed milk Nutrition 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 235000020888 liquid diet Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 235000005985 organic acids Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010011409 Cross infection Diseases 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 229920003175 pectinic acid Polymers 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000273265 Clostridioides difficile ATCC 9689 = DSM 1296 Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000131302 Helichrysum difficile Species 0.000 description 1
- 241001473949 Helicobacter pylori NCTC 11637 = CCUG 17874 = ATCC 43504 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186871 Lactobacillus murinus Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 235000020246 buffalo milk Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 229940050549 fiber Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000020252 horse milk Nutrition 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000037111 immune power Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000021542 oral nutrition Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition having antibacterial activity.
- Liquid foods are widely used in hospitals and geriatric facilities when there is difficulty in swallowing when oral nutrition is difficult.
- Liquid food is nasal cavity, PEG (Percutaneous Endoscopic Gastrostomy), etc., catheter inserted into the body, force that is injected into the body through the tube Generally, liquid food users are elderly people or patients with some disease, and immune power It is easy to infect pathogens that are often reduced.
- liquid food has an antibacterial action, it can be one of the measures to prevent infection of vulnerable persons, but no antibacterial action has been reported so far!
- Non-Patent Document 2 NAKAE Goro, Milk, Meat & Egg Science, Kogaku Publishing, pl32-137, 1996
- Non-Special Reference 3 Kawai Y., Saito, T., Kitazawa, H., and Itoh T., Biosci. Biotech.
- Non-Patent Document 4 Shah, N.P .: Some beneficial effects of probiotic bacteria, Bioscience Microflora, 19,2,99—106,2000
- An object of the present invention is to provide a composition having antibacterial activity that can serve as a means for preventing infection. Means for solving the problem
- the inventors of the present invention who have solved the above-mentioned problems have paid attention to acidic liquid food.
- the liquid food is usually prepared to be neutral, but the acidic liquid food focused by the present inventors is acidic because it contains a fermented milk product as a protein source.
- the present inventors examined the antibacterial action of the acidic liquid food, they showed excellent antibacterial activity against gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa. Furthermore, when the effect on Gram-positive bacteria was examined, surprisingly, the acidic liquid food showed a significantly stronger antibacterial action against Gram-positive bacteria than the fermented milk product.
- Non-patent Document 2 As bacteriocin produced by lactic acid bacteria, nisin produced by Lactococcus lactis subsp. Lactis, gasericin A produced by Lactobacillus gasseri LA-39, etc. are known (Non-patent Document 3).
- Probiotic effects of lactic acid bacteria include infectivity of pathogens on the intestinal epithelium, treatment of infectious diseases caused by the production of antibacterial substances, preventive effect on host immunity by intestinal environment maintenance and macrophage activation, prevention of diarrhea and constipation The effect is known (Non-Patent Document 4).
- a composition prepared using a fermented dairy product has a marked antibacterial activity compared to the raw material. That is, the present invention relates to a composition having an antibacterial action, and is specifically as follows.
- a composition prepared using fermented dairy products comprising carbohydrates, proteins, and lipids, with an energy ratio of carbohydrates 50-70%, proteins 4-25%, lipids 20-30% Yes
- An antibacterial composition having a pH of 4.6 or less
- a method for producing an antibacterial composition characterized by homogenizing and sterilizing,
- FIG. 1 E. coli and Pseudomonas aeruginosa were added to acidic liquid food, neutral liquid food, and fermented milk preparation, and the culture starting power was 3, 6, and 24 hours later.
- FIG. 1 E. coli and Pseudomonas aeruginosa were added to acidic liquid food, neutral liquid food, and fermented milk preparation, and the culture starting power was 3, 6, and 24 hours later.
- FIG. 3 E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, and MRSA are added to a sample prepared by adding lactic acid, acetic acid, and citrate to a neutral liquid diet to pH 4, and starting culture 3, 6, 24 hours After the sample It is a figure showing the number of viable bacteria per lml of food.
- FIG.4 Lactic acid is added to a neutral liquid food with 0.125, 0.25, 0.5, and 1 ml, and E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, and MRSA are added to the sample prepared to pH 4-6.1, and the culture initiation power is 3
- FIG. 6 shows the number of viable bacteria per ml of sample collected after 24 hours.
- FIG.5 H. pylori or difficile bacteria are added to acidic liquid food, neutral liquid food, and fermented milk preparation, and after 3, 6, and 24 hours from the start of culture, the number of viable bacteria per ml of sample collected is calculated.
- FIG. 6 Sample obtained by adding 0.125 ml of lactic acid to a neutral liquid food, adding difficile bacteria to a sample adjusted to pH 4 or pH 6.1, and starting the culture after 3, 6, 24 hours It is a figure showing the number of viable bacteria per lml.
- FIG. 7 MRSA or difficile bacteria are added to acidic liquid food, acidic liquid food 2, neutral liquid food and fermented milk preparation, and the culture starting power is 3, 6, and 24 hours later. It is a figure showing the number of bacteria.
- the present invention provides an antibacterial composition (hereinafter, the composition of the present invention).
- the inventors of the present invention have confirmed the antibacterial action of the acidic liquid food, and based on finding an excellent antibacterial action particularly against gram-positive bacteria.
- the composition of the present invention exhibits acidity.
- the pH is preferably 4.6 or less. More preferably, the pH is less than 4.2, and most preferably, the pH is less than 4.0.
- composition of the present invention contains carbohydrates, proteins, lipids, vitamins and minerals.
- the sugar that can be used in the composition of the present invention is not limited as long as it is edible.
- honey dextrin
- sucrose palatinose
- glucose granulated sugar
- fructose starch syrup
- sugar alcohol sorbitol
- examples thereof include xylitol, maltitol, and the like.
- the protein that can be used in the composition of the present invention is not limited as long as it is edible, but examples thereof include milk-derived proteins such as casein and whey protein, soybean proteins, and animal-derived enzymes such as trypsin and pepsin of these proteins. Examples thereof include hydrolyzates of monothrase and alcalase.
- the lipid that can be included in the composition of the present invention is not limited as long as it is edible.
- castor oil for example, castor oil, rapeseed oil, olive oil, safflower oil containing primary saturated fatty acids and polyunsaturated fatty acids
- corn oil, soybean oil, palm oil, sesame oil, flaxseed oil, perilla oil, evening primrose oil, palm kernel oil, palm oil, and other plant-derived fats and oils, medium-chain fatty acids, EPA, DHA, soybean origin Phospholipids and milk-derived phospholipids can be exemplified, but it is preferable to include one or more kinds of plant-derived fats and oils.
- the polyunsaturated fatty acid having two or more double bonds is contained in a proportion of 10% or more, preferably 20% or more, more preferably 25% or more in the fatty acid composition of the oil or fat.
- the vitamins that can be contained in the composition of the present invention may be any known vitamins that are not particularly limited.
- the minerals that can be contained in the composition of the present invention may be any minerals that are generally added to foods, such as potassium phosphate, potassium carbonate, salty potassium, salty sodium, Calcium lactate, calcium dalconate, calcium pantothenate, calcium caseinate, magnesium chloride, citrate, ferrous sulfate, sodium bicarbonate, sodium pyrophosphate, sodium ascorbate can be included. Any of saccharides, proteins, lipids, vitamins and minerals can contain other components as well as the above specific examples as long as the antibacterial property of the composition is maintained.
- composition of the present invention contains the sugar, protein, and lipid in an energy ratio of 50 to 70% carbohydrate, 4 to 25% protein, and 20 to 30% lipid.
- energy ratio can be obtained as follows.
- Protein energy ratio protein (g) X 4 (kcal / g) ⁇ total energy (kcal) X 100
- Lipid energy ratio Lipid content ( g ) X 9 (kcal / g) ⁇ Total energy content (kcal) X 100
- the energy content of dietary fiber can be calculated based on the Japanese Food Standard Composition Table (issued by the Printing Bureau of the Ministry of Finance, Japan) or the energy conversion factor (2001 Ministry of Health, Labor and Welfare Notification No. 98).
- sugar mass, protein amount, and lipid amount are measured by methods well known to those skilled in the art. Therefore, it can be performed. Preferably, it is performed according to the description in the Japanese food standard ingredient table.
- the amount of dietary fiber can be measured by the Prosky modified method (enzyme-gravimetric method) or HPLC method (AO AC Official Methods of Analysis (2002)) described in the above-mentioned Japanese Food Standard Composition Table. .
- the amount of lactic acid in 100 ml of the composition is OOmg or more, and in a more preferred embodiment, the amount of lactic acid in 100 ml of the composition is 300 mg or more.
- Lactic acid can be quantified by methods well known to those skilled in the art, such as enzymatic methods and HPLC methods. Or, literature describing the method for quantifying organic acids: J Nutr., Jan, 124 (l), 52-60, 1994 ⁇ alactosylsucrose and xylosylrructoside alter digestive tract size and concentrations of cecal organic acids in rats fed diets containing cholesterol and This can be done based on “cholic acid”.
- the composition of the present invention is prepared using a fermented dairy product.
- Fermented dairy products in the present invention refer to livestock milk such as cow's milk, buffalo milk, goat milk, sheep milk, and horse milk, and Z or partially skimmed milk, skimmed milk, reduced whole milk, reduced skimmed milk, and reduced portion.
- This refers to the whole of fermented liquid milk prepared by combining one or more milk raw materials such as skim milk, butter and cream using a starter such as lactic acid bacteria.
- a starter such as lactic acid bacteria.
- natural cheese, yogurt, fermented milk, whey (whey), and whey cheese are included in the fermented milk product of the present invention.
- the cheese in the present invention refers to a product obtained by fermenting milk, notter milk or cream with lactic acid bacteria, or by adding whey to the curdling power obtained by adding an enzyme to milk, notter milk or cream. It doesn't matter whether there is aging or not.
- Lactobacillus bulgancus Streptococcus thermophims can be mainly used, but is limited to these * T, f list is Streptococcus lactis, Streptococcus cremons, streptococcus aiacetilactis, Enterococcus faecium, Enterococcus fecalis, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus acidophilus,
- Lactobacillus rhamnosis Lactobacillus plantarum, Lactobacillus murinus
- Lactobacillus reuteri Lactobacillus brevis, Lactobacillus gasseri, Bifidobacterium longum, Bifidobacterium bifidum, and Bifidobacterium breve can be used.
- Propionibacterium genus Propionibacterium
- Bacteria used for the production of fermented milk products can be used in combination.
- the composition of the present invention may be prepared using any fermented milk product. Preferably, non-aged cheese or yogurt is used, and in a more preferred embodiment, it is prepared using quarq or yogurt.
- Kulk is a kind of non-ripe-molded (fresh) cheese and is characterized by a refreshing flavor and sourness with a low fat content.
- a general method for producing quark will be described below. Sterilize skim milk. Lactobacillus starter (mainly Lactobacillus bulgaricus, Streptococcus thermophilus) 0.5-5% inoculated and fermented. A card is formed when pH 4.6 is reached. Apply to a quark separator to separate the whey and cool the resulting card.
- An example of a quark composition is: total solids 17-19%, protein 11-13%, fat 1%>, carbohydrates 2-8%, lactose 2%>.
- those solidified using a rennet are also included in the torque of the present invention.
- a mixed culture of Lactococcus teremollis and Leuconostoc species belonging to Ratatococcus can be added to and cultured in skim milk, and whey can be removed to obtain a quark.
- non-aged cheese obtained by cutting the curd obtained in the same manner as described above with a cutter and separating whey from warming force S can also be used in the present invention.
- the composition of the present invention is prepared by mixing the above-mentioned fermented milk product with the above-mentioned sugar, protein and lipid and mixing them homogeneously.
- the protein derived from the fermented dairy product has a ratio of 30% by weight or more of the protein in the composition, more preferably 70% by weight or more of the protein in the composition.
- vitamins, minerals, and / or dietary fiber may be added during mixing. Dietary fiber is divided into water-soluble dietary fiber and insoluble dietary fiber, and the difference between the two may be used.
- Water-soluble dietary fibers include pectin (protopectin, pectinic acid, pectinic acid), guar gum hydrolyzate, dalcmannan, galatatomannan, psyllium, corn fiber, alginic acid, alginic acid degradation product, carrageenan, indigestible It can contain dextrin and the like.
- insoluble dietary fiber include crystalline cellulose, beet fiber, wheat bran and the like.
- pectin, guar gum hydrolyzate, or indigestible dextrin can be used.
- fragrances and other Formulations can also be added.
- the container can be filled and subjected to a heat sterilization treatment as necessary to obtain a liquid food or enteral nutrient.
- the calo-heat treatment can be performed under milder conditions than usual.
- the heat sterilization treatment of neutral liquid food is retort sterilization conditions 120-130 ° C, 20-40 minutes, indirect sterilization conditions 140-145 ° C, 4-10 seconds
- the composition of the present invention is 80-90 Retort sterilization at 15 ° C for 15-30 minutes or indirect sterilization at 95-110 ° C for 20-60 seconds.
- mild and powerful sterilization conditions it is possible to improve the flavor and to mix ingredients that are weak against heat.
- the composition of the present invention can be made into a gel form with agar or gelatin, or can be made into a granular food product by spray drying or the like, or can be made into a solid food or pharmaceutical product.
- the composition of the present invention has an antibacterial effect on both gram-negative and gram-positive bacteria. It is particularly effective against gram-positive bacteria.
- the antibacterial activity of lactic acid bacteria fermented products is generally known, but the composition of the present invention has superior antibacterial effects against gram-positive bacteria than fermented dairy products as raw materials.
- This excellent antibacterial effect against gram-positive bacteria is an effect obtained by combining a fermented dairy product with a carbohydrate, protein, lipid, etc. into the composition of the present invention.
- the present inventors have found for the first time that such effects can be obtained by processing a fermented milk product into the composition of the present invention.
- the present inventors confirmed the above-mentioned effects on Staphylococcus aureus, MRSA, caries, and difficile. Antibacterial activity against other gram-positive bacteria such as Streptococcus, uenus Enterococcus, orynebactenum, Bacillus, and C. botulinum Can be expected.
- composition of the present invention is characterized by having the above-mentioned antibacterial activity, but preferably, when the antibacterial activity against Staphylococcus aureus, MRSA, caries, and difficile is measured by the method of the examples,
- the antibacterial activity is less than 2.3 x 10 2 CFU (colony forming unit) Zml after 24 hours of culture, and most preferably the antibacterial activity is less than 10 colonies after 24 hours of culture.
- CFU colony forming unit
- the composition of the present invention can be used as a liquid food or enteral nutrient having an antibacterial effect, particularly an anti-gram positive bacterium effect.
- Liquid food or enteral nutrition itself has antibacterial effect Therefore, it can be used not only as a food but for the purpose of preventing infection.
- a food with an antibacterial activity, an antibacterial activity, or an excellent antibacterial activity against gram-positive bacteria it can be used as a health functional food such as a food for specified health use or a functional nutrition food. it can.
- Many facilities, such as elderly people and hospitalized patients, are considered to be effective and safe preventive measures against nosocomial infections and in-house infections.
- the acidic liquid food For the acidic liquid food, the acidic liquid food prepared according to the formulation shown in Table 1 was used, and the neutral liquid food (May Balance, Meiji Dairies Co., Ltd.) and fermented milk preparation liquid as shown in Table 2 were used as controls. .
- the fermented milk preparation was prepared by adding sterile distilled water to kurk (fermented dairy product) and having the same concentration as the kulk concentration (33 g / 100 ml) in the acidic liquid food prepared by the formulation shown in Table 1.
- the lactic acid bacteria were sterilized by heat treatment at 100 ° C for 10 minutes.
- the manufacturing method of quark is as follows. First, 1%% L acid for skim milk!
- the adjusted fats and oils include fatty acids such as palmitic acid, oleic acid, linoleic acid, linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, and the ratio of fatty acids having double bonds in the fatty acid composition is 25%, n- 6 / n-3 is 7.4%.
- the results are shown in FIGS. Although the acidic liquid food showed the growth inhibitory effect on any of the bacterial species, the antibacterial effect on each bacterial species was unexpectedly interesting.
- the viable count (colony count) of E. coli cultured in fermented milk preparation is as follows: Start of culture: 20,000,000, 3 hours after culture: 8,000,000, 6 hours after culture: 2,500,000, 24 hours after culture: below detection limit
- the number of viable E. coli cultured in acidic liquid food was 20,000,000 at the start of culture, 3,400,000 after 3 hours of culture, 8400 after 6 hours of culture, and 83,000 after 24 hours of culture: detection limit. (In this example, “below the detection limit” means that the number of viable bacteria is less than 10.
- the viable count (number of colonies) of Pseudomonas aeruginosa cultured in fermented milk preparations was 2,000,000, after 3 and 6 hours of culture:
- the viable count of Pseudomonas aeruginosa cultured in an acidic liquid diet was 2,000,000 at the start of culture, 3 hours after culture, and 6 hours after: below the detection limit. That is, the growth-inhibitory effect of acidic liquid food on Escherichia coli and Pseudomonas aeruginosa, which are E. coli gram-negative bacteria, was similar to that of fermented milk preparations.
- Viable counts of Staphylococcus aureus (number of colonies) cultured in fermented milk preparation were 18,000,000 at the start of culture, 7 hours after culture: 7,500,000, 6 hours after culture: 1,000,000
- Viable counts of Staphylococcus aureus cultured in an acidic liquid diet were 18,000,000 at the start of culture, 12,000,000 after culture, 12,000,000, 6 hours after culture: 2, 100,000, and finally the limit of detection after 24 hours of culture. It became the following.
- the number of colonies in the fermented milk preparation was 9,000,000, after 3 hours of culture: 2,900,000, after 6 hours of culture: 400,000, and after 24 hours of culture: 1,300.
- caries fungi cultured in an acidic liquid diet were 9,000,000 at the start of culture, 430,000 after 3 hours of culture: 430,000, and were below the detection limit as early as 6 hours after culture.
- the acidic liquid food not only has antibacterial activity against both gram-negative and gram-positive bacteria, but also far exceeds the antibacterial activity of fermented milk products as raw materials, especially against gram-positive bacteria. It has become clear that it has an antibacterial action.
- Table 2 shows the composition of the neutral liquid food, acidic liquid food, and fermented milk preparation.
- Neutral liquid food contains citrate for pH adjustment, but almost no other organic acids!
- the fermented milk preparation contained 405.lmg / 100ml of lactic acid from lactic acid fermentation.
- Acidic liquid foods contained approximately twice as much lactic acid as fermented milk preparations because calcium lactate was added to ensure the amount of calcium required for liquid foods.
- acid Liquid liquid foods and fermented milk preparations contain many citrate and acetic acids as major organic acids other than lactic acid (Table 2).
- test bacteria and the bacterial solution were prepared in the same manner as in the above-described examination of the antibacterial action of the acidic liquid food.
- 1 ml of lactic acid, 2.3 ml of acetic acid, or lg of citrate (Wako Pure Chemical Industries, Ltd.) was added to a neutral liquid food to adjust the pH to 4.
- lactic acid which is the main organic acid in acidic liquid foods
- the sample was prepared by changing the amount of lactic acid and adding it to the neutral liquid food, and the antibacterial action was examined.
- Test sample in which organic acid contained in fermented milk preparation was added to neutral liquid food in the same amount as in Table 2 (lactic acid: 405.1 mg, acetic acid: 5.3 mg, citrate: 34 mg, formic acid: 0.4 mg)
- the pH of the strain was 5.1, and it did not show any antibacterial activity for any of the bacterial species.
- antibacterial activity against E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, and MRSA was observed (Fig. 3).
- H. pylori As described above, the antibacterial action of the acidic liquid diet against various bacteria was confirmed. Furthermore, the antibacterial action against Helicobacter pylori ATCC43504 (H. pylori) and Clostridium difficile JCM1296 (H. difficile) was examined. Helicobacter pylori is a gram-negative bacterium, and difficile is a gram-positive bacterium. The antibacterial action against H. pylori was examined as follows. First, using a sheep blood agar medium (Eiken Chemical Co., Ltd.), microaerobically cultured at 35 ° C for 3 days, then suspended in sterile physiological saline, and the number of bacteria per ml is about 10 7 to 10 8 .
- the difficile bacterium is anaerobically cultured at 37 ° C for 15 days using GAM agar medium (manufactured by Nippon Pharmaceutical Co., Ltd.) and then suspended in sterile physiological saline.
- the number of bacteria per ml is about 10 8 to 10 9 .
- the sample was diluted appropriately with SCDLP medium (Nippon Pharmaceutical Co., Ltd.), and the number of anaerobic bacteria was anaerobically determined by pour plate culture using GAM agar medium (Nippon Pharmaceutical Co., Ltd.) at 35 ° C for 5-6 days. After culturing under conditions, the number of colonies that developed was counted.
- Example 2 lactic acid was added to a neutral liquid food to examine the antibacterial activity against difficile bacteria.
- 0.125 ml of lactic acid pH 6.1
- Antibacterial activity was confirmed by adding lml of lactic acid (Fig. 6).
- an acidic liquid food having a composition different from that of the acidic liquid food (hereinafter referred to as “acidic liquid food 2”) was prepared, and the antibacterial activity of the acidic liquid food 2 against gram-positive bacteria was determined. And examined.
- the composition of acidic liquid food 2 is shown in Table 4.
- the number of viable MRSA cells cultured in the fermented milk preparation solution was 7,700,000, after 3 hours of culture: 4,900,000, after 6 hours of culture: 4,600,000, 24 hours after culture: 920,000 compared to 920,000
- the number of viable MRSA cultivated was 7,700,000 at the beginning of the culture, but as early as 3 hours after culture: 5,600, after 6 hours of culture: 70, and finally after 24 hours of culture: below the detection limit.
- the number of viable difficile bacteria cultured in fermented milk preparations was 9,100,000 at the beginning of the culture, 3 hours after the culture: 10,000,000, 6 hours after the culture: 7,000,000, 24 hours after the culture: 220,000
- the viable count of difficile cultivated in acidic liquid food 2 is drastically reduced to 12,000,000, after 3 hours of culture: 9,300,000, after 6 hours of culture: 1,400,000, and finally to the limit of detection after 24 hours of culture. It became the following. Even when difficile bacteria were cultured in the acidic liquid diet of Example 1, the culture started: 9100,000, after 3 hours of culture: 2400000, after 6 hours of culture: 44000, showing a sharp decline, and below the detection limit after 24 hours of culture It became.
- acidic liquid food 3 was prepared according to the formulation shown in Table 5. Table 6 shows the energy ratios of the acidic liquid food, acidic liquid food 2, and acidic liquid food 3 in this example.
- the composition of the present invention is particularly effective against Gram-positive bacteria.
- the composition of the present invention can serve as an infection protection means other than antibiotics for easily infected persons such as the elderly. Since the liquid food itself has an antibacterial action, it can be said to be a simple and effective method for preventing nosocomial infections through catheters and the like.
- the composition of the present invention which is an anti-gram-positive bacterial composition, is highly practical, considering that hygiene-critical bacterial species such as MRSA, which is a representative cause of opportunistic infections, are gram-positive bacteria. .
- composition of the present invention contains fermented dairy products, it has the effect of suppressing the adherence of pathogenic bacteria to the intestinal epithelium, the effect of treating and preventing infectious diseases caused by the production of antibacterial substances, the maintenance of the intestinal environment and macrophage activity. Probiotic effects of lactic acid bacteria such as stimulating host immune function and preventing diarrhea and constipation can also be expected.
- the composition of the present invention can be an oral antibacterial food or medicine, and is extremely useful in terms of nutrition and health.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006511790A JP4911700B2 (ja) | 2004-03-31 | 2005-03-31 | 抗菌性組成物 |
CN2005800170105A CN1960738B (zh) | 2004-03-31 | 2005-03-31 | 抗菌性组合物 |
US10/593,550 US20070172547A1 (en) | 2004-03-31 | 2005-03-31 | Antibacterial compositions |
NZ550792A NZ550792A (en) | 2004-03-31 | 2005-03-31 | Antibacterial compositions |
AU2005228768A AU2005228768C1 (en) | 2004-03-31 | 2005-03-31 | Antibacterial compositions |
KR1020127006827A KR101155735B1 (ko) | 2004-03-31 | 2005-03-31 | 항균성 조성물 |
CA002562947A CA2562947A1 (en) | 2004-03-31 | 2005-03-31 | Antibacterial composition comprising cheese and low ph |
EP05727707.1A EP1743647B1 (en) | 2004-03-31 | 2005-03-31 | Antibacterial composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004107031 | 2004-03-31 | ||
JP2004-107031 | 2004-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005094850A1 true WO2005094850A1 (ja) | 2005-10-13 |
Family
ID=35063516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006253 WO2005094850A1 (ja) | 2004-03-31 | 2005-03-31 | 抗菌性組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070172547A1 (ja) |
EP (2) | EP1743647B1 (ja) |
JP (1) | JP4911700B2 (ja) |
KR (2) | KR101155735B1 (ja) |
CN (2) | CN1960738B (ja) |
AU (1) | AU2005228768C1 (ja) |
CA (1) | CA2562947A1 (ja) |
NZ (1) | NZ550792A (ja) |
WO (1) | WO2005094850A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009274964A (ja) * | 2008-05-12 | 2009-11-26 | Sanei Gen Ffi Inc | 経管投与用ゲル状酸性濃厚流動食又は栄養剤 |
WO2012132913A1 (ja) * | 2011-03-29 | 2012-10-04 | 株式会社明治 | クロストリジウム・ディフィシル増殖阻害剤 |
JP2014091679A (ja) * | 2012-10-31 | 2014-05-19 | Katsumi Tsukuda | 体臭抑制用組成物、体臭抑制用組成物の製造方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8241690B2 (en) | 2008-11-14 | 2012-08-14 | Kraft Foods Global Brands Llc | Method of making fresh cheese with enhanced microbiological safety |
TWI612902B (zh) * | 2009-11-30 | 2018-02-01 | Meiji Co Ltd | 一種組成物用於製造改善腸道功能組成物的用途及其製備方法 |
EP2455094A1 (en) * | 2010-11-11 | 2012-05-23 | Nestec S.A. | Non-replicating probiotic micro-organisms protect children against gastrointestinal infections |
US9408878B2 (en) * | 2010-12-17 | 2016-08-09 | Compagnie Gervais Danone | Lactococcus lactis strains for use in improving digestive condition |
EP2838365A4 (en) * | 2012-04-16 | 2016-04-13 | Cascades Canada Ulc | ANTIMICROBIAL COMPOSITIONS AND USES THEREOF |
JP6098047B2 (ja) * | 2012-06-27 | 2017-03-22 | 日油株式会社 | 液状栄養組成物 |
CN104605463A (zh) * | 2015-01-19 | 2015-05-13 | 吉林大学 | 一种提高尼生素抗革兰氏阳性菌作用的增效剂 |
US11213055B2 (en) | 2017-12-28 | 2022-01-04 | Third Wave Bioactives, Llc | Fermentate compositions and methods of making and using the same |
CN108184997B (zh) * | 2018-01-18 | 2021-05-28 | 北京科拓恒通生物技术股份有限公司 | 一种饮用型酸乳用稳定剂、饮用型酸乳及其制备方法 |
KR20210099382A (ko) * | 2020-02-04 | 2021-08-12 | 엘지전자 주식회사 | 항균제의 항균력 평가 방법 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59187734A (ja) * | 1983-04-08 | 1984-10-24 | Yukijirushi Roorii Kk | ゲル状発酵乳食品 |
JPS6016931A (ja) * | 1983-07-08 | 1985-01-28 | Meiji Milk Prod Co Ltd | 重症の術前術後患者用栄養組成物の製造法 |
JPS6420057A (en) * | 1987-07-16 | 1989-01-24 | Calpis Food Ind Co Ltd | Fat-containing concentrated lactic fermentation drink and preparation thereof |
JPH03285641A (ja) * | 1990-03-31 | 1991-12-16 | Snow Brand Milk Prod Co Ltd | 殺菌液状発酵乳および殺菌乳酸菌飲料の製造法 |
JPH05252896A (ja) * | 1992-03-10 | 1993-10-05 | Meiji Milk Prod Co Ltd | 腎臓病患者用液状調製栄養食品 |
JPH0698717A (ja) * | 1992-09-17 | 1994-04-12 | Meiji Milk Prod Co Ltd | 長期療養患者用液状調製栄養食品 |
JPH07155103A (ja) * | 1993-12-08 | 1995-06-20 | Shikoku Nyugyo Kk | 乳酸菌発酵液の製造方法 |
JPH0970256A (ja) * | 1995-09-05 | 1997-03-18 | Lion Corp | チーズ含有流動性組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3963836A (en) * | 1972-05-10 | 1976-06-15 | Lever Brothers Company | Preparation of yogurt and quark |
CH580920A5 (ja) * | 1973-09-20 | 1976-10-29 | Zentralschweizerischer Milchve | |
GB8604133D0 (en) * | 1986-02-19 | 1986-03-26 | Unilever Plc | Spreads |
US6156320A (en) * | 1993-02-05 | 2000-12-05 | Harry Parsekian | Fermented milk nutraceuticals |
TW408153B (en) * | 1998-01-09 | 2000-10-11 | Asahi Chemical Ind | Cellulose-containing composite, process for its preparation and use thereof |
JP4328065B2 (ja) * | 2002-07-17 | 2009-09-09 | 日油株式会社 | 経腸栄養剤 |
-
2005
- 2005-03-31 CA CA002562947A patent/CA2562947A1/en not_active Abandoned
- 2005-03-31 KR KR1020127006827A patent/KR101155735B1/ko active IP Right Grant
- 2005-03-31 NZ NZ550792A patent/NZ550792A/en unknown
- 2005-03-31 AU AU2005228768A patent/AU2005228768C1/en active Active
- 2005-03-31 US US10/593,550 patent/US20070172547A1/en not_active Abandoned
- 2005-03-31 CN CN2005800170105A patent/CN1960738B/zh active Active
- 2005-03-31 EP EP05727707.1A patent/EP1743647B1/en active Active
- 2005-03-31 WO PCT/JP2005/006253 patent/WO2005094850A1/ja active Application Filing
- 2005-03-31 CN CN200910222826A patent/CN101721426A/zh not_active Withdrawn
- 2005-03-31 JP JP2006511790A patent/JP4911700B2/ja active Active
- 2005-03-31 KR KR1020067022476A patent/KR20060135041A/ko not_active Application Discontinuation
- 2005-03-31 EP EP11009093.3A patent/EP2436274B1/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59187734A (ja) * | 1983-04-08 | 1984-10-24 | Yukijirushi Roorii Kk | ゲル状発酵乳食品 |
JPS6016931A (ja) * | 1983-07-08 | 1985-01-28 | Meiji Milk Prod Co Ltd | 重症の術前術後患者用栄養組成物の製造法 |
JPS6420057A (en) * | 1987-07-16 | 1989-01-24 | Calpis Food Ind Co Ltd | Fat-containing concentrated lactic fermentation drink and preparation thereof |
JPH03285641A (ja) * | 1990-03-31 | 1991-12-16 | Snow Brand Milk Prod Co Ltd | 殺菌液状発酵乳および殺菌乳酸菌飲料の製造法 |
JPH05252896A (ja) * | 1992-03-10 | 1993-10-05 | Meiji Milk Prod Co Ltd | 腎臓病患者用液状調製栄養食品 |
JPH0698717A (ja) * | 1992-09-17 | 1994-04-12 | Meiji Milk Prod Co Ltd | 長期療養患者用液状調製栄養食品 |
JPH07155103A (ja) * | 1993-12-08 | 1995-06-20 | Shikoku Nyugyo Kk | 乳酸菌発酵液の製造方法 |
JPH0970256A (ja) * | 1995-09-05 | 1997-03-18 | Lion Corp | チーズ含有流動性組成物 |
Non-Patent Citations (2)
Title |
---|
See also references of EP1743647A4 * |
SUGAMATA A. T AL: "Atarashii Yoghurt-Honey (Y-H) Seizai YH8280 no Shiyo Keiken (Dai 1 Po)", NESSHO, vol. 9, no. 2, March 1984 (1984-03-01), pages 25 - 30, XP002994204 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009274964A (ja) * | 2008-05-12 | 2009-11-26 | Sanei Gen Ffi Inc | 経管投与用ゲル状酸性濃厚流動食又は栄養剤 |
WO2012132913A1 (ja) * | 2011-03-29 | 2012-10-04 | 株式会社明治 | クロストリジウム・ディフィシル増殖阻害剤 |
JP6029242B2 (ja) * | 2011-03-29 | 2016-11-24 | 株式会社明治 | クロストリジウム・ディフィシル増殖阻害剤 |
JP2017019833A (ja) * | 2011-03-29 | 2017-01-26 | 株式会社明治 | クロストリジウム・ディフィシル増殖阻害剤 |
JP2014091679A (ja) * | 2012-10-31 | 2014-05-19 | Katsumi Tsukuda | 体臭抑制用組成物、体臭抑制用組成物の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005094850A1 (ja) | 2008-02-14 |
CN101721426A (zh) | 2010-06-09 |
AU2005228768B8 (en) | 2010-06-10 |
AU2005228768A1 (en) | 2005-10-13 |
CA2562947A1 (en) | 2005-10-13 |
AU2005228768B2 (en) | 2010-05-13 |
CN1960738A (zh) | 2007-05-09 |
EP1743647B1 (en) | 2016-12-28 |
AU2005228768C1 (en) | 2010-11-18 |
EP1743647A4 (en) | 2009-07-15 |
EP2436274B1 (en) | 2016-12-28 |
KR20120034825A (ko) | 2012-04-12 |
CN1960738B (zh) | 2011-05-04 |
JP4911700B2 (ja) | 2012-04-04 |
NZ550792A (en) | 2010-05-28 |
KR101155735B1 (ko) | 2012-06-12 |
KR20060135041A (ko) | 2006-12-28 |
EP2436274A1 (en) | 2012-04-04 |
EP1743647A1 (en) | 2007-01-17 |
US20070172547A1 (en) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4911700B2 (ja) | 抗菌性組成物 | |
Soccol et al. | The potential of probiotics: a review. | |
JP5951087B2 (ja) | インフルエンザ感染症の予防組成物 | |
US10925906B2 (en) | Composition for improving brain function for neonates | |
RU2426438C2 (ru) | Синбиотическая композиция для коррекции нарушений микробиоценоза кишечника и повышения общей резистентности организма и способ ее получения (варианты) | |
WO2015087919A1 (ja) | 抗菌ペプチド誘導剤 | |
Morya et al. | Advancement in acidophilus milk production technology | |
BG66485B1 (bg) | Щам lactobacillus delbrueckii subsp. bulgaricus с широк спектър на приложение | |
Ouwehand et al. | Cheese as a carrier for probiotics: in vitro and human studies | |
Shori et al. | Advances in Biotechnology | |
Zhang | Chemical Composition, Probiotic Survivability and Shelf Life Studies of Symbiotic Buttermilk | |
Ganesh | A novel yogurt product with Lactobacillus acidophilus | |
RU2575103C2 (ru) | Кисломолочный напиток | |
Eminoglu et al. | Probiotic Dairy Foods | |
RU2541778C2 (ru) | Способ получения бактериального концентрата и его применение в качестве пробиотической биологически активной добавки к пище. | |
JP5851242B2 (ja) | チオレドキシン誘導活性を有する乳酸菌ならびにチオレドキシンを介する生体傷害の予防および/または改善用の飲食品および医薬品 | |
JPWO2015133638A1 (ja) | 肺炎球菌感染予防剤 | |
Minj et al. | 10 Beneficial Effects of Dairy | |
Soccol et al. | Mogućnosti primjene probiotika | |
Minj et al. | 10 Beneficial Effects of Dairy Foods Enriched with Prebiotics and Probiotics | |
UA12088U (en) | Method of making fermented milk products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511790 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2562947 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005228768 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 550792 Country of ref document: NZ |
|
REEP | Request for entry into the european phase |
Ref document number: 2005727707 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727707 Country of ref document: EP Ref document number: 1020067022476 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2005228768 Country of ref document: AU Date of ref document: 20050331 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005228768 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580017010.5 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067022476 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727707 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007172547 Country of ref document: US Ref document number: 10593550 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10593550 Country of ref document: US |